<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071876</url>
  </required_header>
  <id_info>
    <org_study_id>P09-08 / BF2.649</org_study_id>
    <secondary_id>2009-017248-14</secondary_id>
    <nct_id>NCT01071876</nct_id>
  </id_info>
  <brief_title>BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS</brief_title>
  <acronym>HAROSA1</acronym>
  <official_title>BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter randomized double blind study versus placebo during 12 weeks with at first, an
      escalating dose period followed by stable dose period at the selected dose.

      This double-blind period can be followed by a 9 months open-label period if the patient
      wishes to continue with the study product.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first period (12 weeks double blind period) will aim at demonstrating the efficacy and
      safety of BF2.649 by verifying whether the results of BF2.649 are superior to those of
      placebo.

      The aim of the second period (open label extension phase) will be to assess the long-term
      tolerance, as well as the maintenance of the BF2.649 efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ESS change (Epworth Sleepiness Scale)</measure>
    <time_frame>at week 12 /52 versus baseline</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>BF2.649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BF2.649 capsules dosed at 5mg, 10 mg, 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules of Placebo containing lactose with low, medium and high dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule in the morning before breakfast</description>
    <arm_group_label>BF2.649</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule in the morning before breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with OSA treated by nCPAP but still complaining with EDS

          -  ESS score &gt; or = 12

        Exclusion Criteria:

          -  patient suffering from insomnia without OSA

          -  co-existing narcolepsy

          -  patient with sleep debt not due to OSA

          -  acute or chronic severe disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyne De Paillette, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep disorder</keyword>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>excessive daytime sleepiness</keyword>
  <keyword>patients with OSA treated by CPAP presenting EDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

